A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer
Phase 2
- Conditions
- ECOG PS2 patients with advanced non-small cell lung cancer
- Registration Number
- JPRN-C000000097
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1. Prior radiotherapy to evaluable disease unless subsequent progression at that site 2. Prior brain metastases if not clinically stable after surgery and/or radiotherapy 3. Uncontrolled hypertension, unstable angina pectoris, myocardial infarction <6 months before enrollment or congestive heart failure 4. Active concomitant malignancy requiring treatment. 5. Uncontrolled serious active infection 6. Pre-existing grade 2 neuropathy 7. Pregnancy or lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method